<DOC>
	<DOCNO>NCT02000154</DOCNO>
	<brief_summary>This extension study study investigate long term safety SyB L-1101 administer intravenously every 4 week patient complete 8 cycle study 2011005 whose purpose investigate tolerability SyB L-1101 administer intravenously patient recurrent/relapsed refractory myelodysplastic syndrome . Antitumor effect also investigate study .</brief_summary>
	<brief_title>Long Term Safety Study SyB L-1101 Patients With Recurrent/Relapsed Refractory Myelodysplastic Syndrome ( MDS ) - Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Patients must satisfy follow condition list . 1 . Patients enrol study 2011005 SyB L1101 Patients With Myelodysplastic Syndrome . 2 . Patients judge disease progression* progressive disease/relapsed** end cycle 8 study 2011005 . * hematologic remission accord IWG 2006 criterion ** hematologic improvement accord IWG 2006 criterion 3 . Patients meet continuation criteria*** Cycle 8 week 2 ( Day 15Â±3 ) study 2011005 . ***defined study 2011005 protocol 4 . Patients expect survive least three month longer . 5 . Patients score 0 2 Eastern Cooperative Oncology Grou ( ECOG ) Performance Status ( P.S. ) . 6 . Patients adequate function major organ ( heart , lung , liver , kidney , etc. ) . Aspartate aminotransferase ( AST ) : 3.0 time upper boundary reference range institution Alanine aminotransferase ( ALT ) : 3.0 time upper boundary reference range institution Total bilirubin : 1.5 time upper boundary reference range institution Serum creatinine : 1.5 time upper boundary reference range institution ECG : abnormal finding require treatment Echocardiography : abnormal finding require treatment 7 . Patients personally sign informed consent document participation study . Patients satisfy follow condition enrol study . 1 . Patients anemia ( haemolytic anaemia , gastrointestinal haemorrhage , etc . ) cause factor MDS . 2 . Patients obvious infectious disease ( include viral infection ) . 3 . Patients serious complication ( liver failure , renal failure , etc. ) . 4 . Patients complication serious heart disease ( myocardial infarction , ischemic heart disease , etc . ) 5 . Patients serious gastrointestinal condition ( severe significant nausea/vomiting , diarrhea , etc . ) 6 . Patients serious bleed tendency ( disseminate intravascular coagulation ( DIC ) , internal hemorrhage , etc. ) . 7 . Ascites require active medical management include paracentesis , hyponatremia ( define serum sodium value &lt; 130 milliequivalent/L ) . 8 . Patients addiction legal illegal drug , alcohol dependency . 9 . Patients nurse , pregnant may become pregnant . 10 . Patients consent follow contraceptive measure . Patients avoid sexual intercourse sexual partner use follow contraceptive method time period : male patient administration period trial six month end administration ; female patient administration period trial , second menstrual period confirm end administration ( case female patient menstrual period , two month end administration ) . ( 1 ) Male patient : The patient always use condom . For effective contraception , recommend female partner also use contraceptive method female patient . ( 2 ) Female patient : Female patient may become pregnant use one type follow contraceptive method . In addition , male partner always use condom . Oral contraceptive ( birth control pill ) Intrauterine device ( IUD ) Tubal ligation 11 . Other patient judge unsuitable investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>